OAS Logo

Log in

Recent Posts from the OASIS Newsletter

OASIS Newsetter Summer 2023

01 Sep 2023 7:59 AM | Krista DuRapau (Administrator)

Summer 2023 Issue

Greetings OAS Members!

2023 has been a year of excitement.  Next year we are hosting the 37th Annual OAS Scientific Meeting in Houston, Texas on February 9-10, 2024.  The society first met in Houston, so this journey has brought us full circle to where it all began.  As the fourth largest city in the US, Houston is a fantastic city to get to know.  We have a wealth of academic support from our partners in the Texas Medical Center - the largest medical center in the world!!  We are hoping that a central location will appeal to our bicoastal colleagues and with two airports, there are many options to get here.  

Our society is also working on increasing our international footprint with involvement from our colleagues in the British and Indian Ophthalmic Anesthesia Organizations.  The OAS continues it’s tradition of being an organization that brings together ophthalmologists, anesthesiologists, registered nurse anesthetists and other clinicians to improve the quality of care for our patients.

Can’t wait to see you in Houston!

Maggie Jeffries, MD

President, Ophthalmic Anesthesia Society

The OAS Annual Scientific Meetings are held each year and feature scientific programs designed to feature the latest education, techniques, and research in the realm of ophthalmic surgery and anesthesia. We look forward to meeting you in Houston, February 9-10, 2024. 

·        Hands-on workshops with certificates of attendance

·        Exclusive lectures from anesthesia, ophthalmology and surgery experts 

·        Round table events with other physicians and registered nurses  

·        Valuable networking opportunities

·        Slides and notes from speakers at all presentations

Whether you are an anesthesiologist, CRNA, ophthalmologist, nurse, resident or student, there is something for everyone at the OAS Annual Scientific Meeting.

Find out more

Budget now to renew your membership for next year and benefit from reduced registration at the conference.

Membership Categories

Annual Rate





  Associates (RN, PA, Surgical Techs)


  Resident/ Fellow


OAS Members enjoy exclusive benefits:

No formal gatherings are scheduled for the current year. However, we encourage you to avail yourself of a comprehensive array of resources, including last year's presentations and an extensive repository of information accessible via past newsletters. These invaluable assets facilitate engagement with the scientific community, fostering collaborative opportunities among peers. Anticipate forthcoming dynamic updates on society initiatives that promise enhanced interactivity and engagement.

Meet the OAS Board


Maggie Jeffries, MD, Avanti Anesthesia


Jefferson Doyle, MD, Johns Hopkins

Immediate Past-President   

George Dumas, MD, University of Alabama Birmingham


Kay Phelan, CRNA, Connecticut Eye Surgery Center


Robert Gauvin, CRNA, Anesthesia Professionals


Eric Fry, MD, Fry Eye Associates, P.A.

Pete Spitellie, MD, JJM Medical Services

Elaine Liew, MD, University of California, Los Angeles

Tina Tran, MD, Johns Hopkins

Brenton Rains, CRNA, Center for Sight 

Scientific Advisory Chair                

Randolf Harvey, CRNA, Florida Eye Clinic / ASC

At-Large Director                

Vinodkumar Singh, MD, University of Alabama Birmingham


Take a survey for a chance to win $250 AMAZON Card

OAS President, Dr. Maggie Jeffries, recently published a paper regarding opiate use in cataract surgery. Below is a follow up survey she helped design to gain even more information to share with the ophthalmic anesthesia industry. Please take a few minutes to complete the survey, results will be shared later this year in a recap from Dr. Jeffries. A randomly selected winner will receive an electronic $250 Amazon Card. Be sure to fill out the survey for a chance to win!

Take the survey now

GLP-1 receptor agonists and sedation for Ophthalmic surgery

Many of us are now aware of the reports of retained gastric contents in patients take glucagon-like peptide-1 (GLP-1) receptor agonists despite being appropriately NPO.  These medications work by the inhibition of gastric emptying and stimulation of insulin production and reduction in glucagon secretion leading to lower insulin levels.   The delayed gastric emptying reduces hunger, leading to a reduction in food intake and subsequent weight loss. 

It is advisable to familiarize yourself with the generic and brand names of these medication and ensure that your preoperative staff is educated as well.  There are various routes of administration such as oral pills and subcutaneous injections and administration could be daily or weekly.  As of publication of this article, the current FDA approved GLP-1 medications are:

Dulaglutide (trulicity)

Exenatide (Bydureon, Byetta)

Semaglutide (Ozempic, Wegovy, Rybelsus)

Liraglutide (Victoza, Saxenda)

Lixisenatide (Adlyxin)

Tirzapatide (Mounjaro)

If the patient has GI symptoms such as nausea, vomiting, dyspepsia and abdominal distention, current evidence indicates there is an increased likelihood of retained gastric contents.2 Because of concerns over an increased risk of aspiration associated with GLP-1 agonists, the ASA Task Force on Preoperative Fasting reviewed the limited existing literature and compiled the following recommendations for elective procedures.3 This is taken directly from their statement which is linked in the references below. 

“Day or week prior to the procedure:

·        Hold GLP-1 agonists on the day of the procedure/surgery for patients who take the medication daily.

·        Hold GLP-1 agonists a week prior to the procedure/surgery for patients who take the medication weekly.

·        Consider consulting with an endocrinologist for guidance in patients who are taking GLP-1 agonists for diabetes management to help control their condition and prevent hyperglycemia (high blood sugar).

Day of the Procedure:

  • ·        Consider delaying the procedure if the patient is experiencing GI symptoms such as severe nausea/vomiting/retching, abdominal bloating or abdominal pain and discuss the concerns of potential risk of regurgitation and aspiration with the proceduralist or surgeon and the patient.
  • ·        Continue with the procedure if the patient has no GI symptoms and the GLP-1 agonist medications have been held as advised.
  • ·        If the patient has no GI symptoms, but the GLP-1 agonist medications were not held, use precautions based on the assumption the patient has a “full stomach” or consider using ultrasound to evaluate the stomach contents. If the stomach is empty, proceed as usual. If the stomach is full or if the gastric ultrasound is inconclusive or not possible, consider delaying the procedure or proceed using full stomach precautions. Discuss the potential risk of regurgitation and aspiration of gastric contents with the proceduralist or surgeon and the patient.
  • ·        Full stomach precautions should be used in patients who need urgent or emergency surgery.”

This is all well and good for general anesthetics, but what about procedures/surgery under light sedation such as cataract surgery?  These medications are being prescribed in ever increasing amounts and not always by legitimate health care providers.  Compounding pharmacies are now offering these medications as well as online websites.  Further concerning is that patients may not disclose taking these medications as they don’t see it as a “medication.”

The Ophthalmic Anesthesia Society has received numerous inquiries as to what guidance, if any, we can provide.  We recommend that patients be specifically asked if they are taking any GLP-1 medications, in what dose and delivery form, for what indication, and if they are having any GI side effects.  Preferably this occurs at the surgeon’s office so that an intervention in dosing might be made.  At the very least, sedation should be tailored to keep these patients as awake as possible.  As sedation is a spectrum from light to deep, the final decision on how to proceed remains with the anesthesia provider and should be influenced by both patient and surgical factors.  The OAS will continue to monitor the available evidence which will continue to evolve as more research is performed. 

It is our expectation to perform a survey of our members regarding their anesthesia practices related to GLP-1 medications and present the data at our annual meeting.  There will be a lecture and further discussion regarding this important subject.  See you there!!

Vinodkumar Singh, MD FRCA MRCP


Department of Anesthesiology and Perioperative Medicine

Division of Critical Care Medicine

University of Alabama at Birmingham Hospital

619 S. 19th Street JT 804

Birmingham, AL 35249


  1. Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: A case report. Can J Anesth. 2023. DOI: 10.1007/s12630-023-02440-3.
  2. Silveira SQ, da Silva LM, Abib ACV et al. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023; 87: 111091.
  3. Powell K. Did you know that the ASA has offered guidance on preoperative management of patients on glucagon-like peptide-1 (GLP-1) receptor agonists for elective procedures?  Online, August 2, 2023.

Copyright © 2023 Ophthalmic Anesthesia Society. All Rights Reserved.

Powered by Wild Apricot Membership Software